Long-Term Care Facilities, Therapies and Virus

Long-Term Care Facilities

Therapies

Virus

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

FEBRUARY 1, 2021

million shots have now been administered in long-term care facilities, according to the U.S. 1.351 variant contains a key mutation that appears to allow the virus to elude the full power of antibody treatments and vaccines. “I’m optimistic, this is good.” ” As of Saturday, more than 3.5

Nurses

Nurses Vaccine Long-Term Care Facilities Virus

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

SEPTEMBER 18, 2020

The Marburg facility is expected to start the production of mRNA formulation for a Covid-19 vaccine in the first half of 2021, pending regulatory authorization or approval.

Vaccine

Vaccine Long-Term Care Facilities Clinical Supply Laboratories

Join 15,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Chemical Biology and Drug Design

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials

Trials Long-Term Care Facilities Virus Government

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.

Therapies

Therapies Hospitals Treatment FDA Approval

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. The trial will evaluate a single dose of firibastat 1000mg compared to placebo, on top of the patients’ current therapy.

Long-Term Care Facilities

Long-Term Care Facilities Trials Virus Clinical Trials

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Government

Government Long-Term Care Facilities Hospitals Treatment

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. who require oxygen therapy due to COVID-19, OR. In the U.S.,

Treatment

Treatment Hospitals Long-Term Care Facilities Virus

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

The Pharma Data

OCTOBER 28, 2020

government to meet Operation Warp Speed goals – are fundamental to enable the most widespread and equitable access to our potential therapy,” said David A. government has committed that patients will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product’s administration.

Government

Government Long-Term Care Facilities Hospitals Therapies

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment

Treatment FDA Hospitals Long-Term Care Facilities

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals

Hospitals Treatment Trials Long-Term Care Facilities

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

The Pharma Data

DECEMBER 19, 2020

Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. Department of Health and Human Services (HHS) for review and adoption.

Vaccine

Vaccine Long-Term Care Facilities FDA Licensing

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

The Pharma Data

MARCH 5, 2021

The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued. Lilly Antibody Therapies Around the World. who require oxygen therapy due to COVID-19, OR. Ricks, Lilly’s chairman and CEO.

Treatment

Treatment Hospitals Long-Term Care Facilities Therapies

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

MARCH 11, 2021

This new Phase 3 cohort of BLAZE-1 included 769 high-risk patients, aged 12 and older with mild to moderate COVID-19 (therapy: n=511; placebo: n=258). who require oxygen therapy due to COVID-19, OR. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Hospitals

Hospitals Trials Long-Term Care Facilities Treatment

Drug Discovery Digest

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

Trending Sources

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

Clinical Catch-Up: January 18-22 | BioSpace

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

Stay Connected